InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
IL-12 Reporter HEK 293 Cells | Intratumoral immunotherapy relies on B and T cell collaboration. | 2022 | Sci Immunol. | Sagiv-Barfi I. et al. | DOI: 10.1126/sciimmunol.abn5859 |
IL-12 Reporter HEK 293 Cells | Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of pla... | 2022 | Mol Ther Oncolytics | Lee J.Y. et al. | DOI: 10.1016/j.omto.2022.04.005 |
Recombinant anti-mouse PD-1 antibody - Clone RMP1-14 (D265A) | Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of pla... | 2022 | Mol Ther Oncolytics | Lee J.Y. et al. | DOI: 10.1016/j.omto.2022.04.005 |
QUANTI-Blue™ | Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of pla... | 2022 | Mol Ther Oncolytics | Lee J.Y. et al. | DOI: 10.1016/j.omto.2022.04.005 |
IL-12 Reporter HEK 293 Cells | A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control... | 2022 | Sci Immunol. | Xue D. et al. | DOI: 10.1126/sciimmunol.abi6899 |
Recombinant human IL-18 protein - Bioactive cytokine | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
IL-12 Reporter HEK 293 Cells | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
HEK-Blue™ Selection | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
QUANTI-Blue™ | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
IL-18 Reporter HEK 293 Cells | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
CL075 (3M002) | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
ssRNA40/LyoVec™ | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
HEK-Blue™ Detection | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
2’3’-cGAM(PS)2 (Rp/Sp) | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
Poly(I:C) (HMW) VacciGrade™ | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
TL8-506 | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
Human TLR7 Reporter HEK293 Cells (NF-κB) | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
Pam3CSK4 VacciGrade™ | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
R848 VacciGrade™ | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
Human TLR8 Reporter HEK293 Cells (NF-κB) | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |